UNCY

Unicycive Therapeutics Inc

3.74

Oct 30 • 3:59 PM ET -0.07 (-1.84%)

3.26

Aftermarket • 7:59 PM ET -0.48 (-12.78%)

Healthcare Biotechnology USA Micro NASD

Peers: ARDX CRMD PROK TVTX VERA XRTX ICU CALC AUPH GYRE

| Held by: VTI IWM VXF IWO VTWO IWC GSSC VTWG IWN RSSL

Scroll to Statements

Index	RUT
Market Cap	104.18M
Enterprise Value	43.50M
Income	-35.22M
Sales	0.00M
Book/sh	1.91
Cash/sh	2.20
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Jul 13, 2021

P/E	-
Forward P/E	2.66
PEG	-
P/S	-
P/B	1.96
P/C	1.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.81
Current Ratio	3.81
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.60
EPS next Y	1.41
EPS next Q	-0.35
EPS this Y	25.33%
EPS next Y	212.94%
EPS next 5Y	-
EPS past 3/5Y	48.15% -2.40%
Sales past 3/5Y	- -
EPS Y/Y TTM	43.63%
Sales Y/Y TTM	-
EPS Q/Q	87.79%
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	87.26% -

Insider Own	4.24%
Insider Trans	0.00%
Inst Own	45.34%
Inst Trans	5.07%
ROA	-69.05%
ROE	-101.07%
ROIC	-66.06%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.50%
SMA50	-17.59%
SMA200	-38.71%
Trades

Shs Outstand	27.86M
Shs Float	26.68M
Short Float	18.29%
Short Ratio	5.49
Short Interest	4.88M
52W High	8.74 -57.21%
52W Low	3.35 11.64%
Volatility	6.84% 6.50%
ATR (14)	0.25
RSI (14)	40.45
Beta	1.87
Rel Volume	1.46
Avg Volume	888.32K
Volume	1,300,302

Perf Week	-3.86%
Perf Month	-17.80%
Perf Quarter	-26.01%
Perf Half Y	-51.24%
Perf YTD	-35.18%
Perf Year	-22.25%
Perf 3Y	-38.92%
Perf 5Y	-87.06%
Perf 10Y	-
Recom	1.00
Target Price	29.56
Prev Close	3.81
Price	3.74
Change %	-1.84%

Consensus

Strong Buy

Avg. Price Target

$29.56

Implied Upside

+690.4%

Analysts3incl. previous ratings

Rating Distribution3 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 01, 2026	Initiated	RB. Riley Securities	Buy	$22	+488.2%
Apr 21, 2025	Initiated	GGuggenheim	Buy	$6	+60.4%
Apr 04, 2024	Initiated	PPiper Sandler	Overweight	$9	+140.6%

Oct-21-26 05:35PM	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027 (InvestorsHub)
07:05AM	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027 (GlobeNewswire)
03:50AM	Kaplan Fox Urges Investors of Unicycive Therapeutics, Inc. (UNCY) to Seek a Leadership Role Before November 2, 2026 (Newsfile)
Oct-19-26 03:50AM	Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors Seeking Recovery to Contact the Firm Before November 2, 2026 (Newsfile)
Oct-01-26 07:05AM	Unicycive Therapeutics Appoints Meredith Manning to Board of Directors (GlobeNewswire)
03:21PM	Loading…
Sep-29-26 03:21PM	UNCY LAWSUIT: Unicycive Therapeutics Investors Should Contact Block & Leviton to Possibly Recover Losses (Newsfile)
07:05AM	Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate (GlobeNewswire)
Sep-15-26 03:57PM	Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility to Ensure it Resolved the FDA's Previously Noted Deficiencies (Newsfile) -8.54%
Sep-11-26 02:31PM	Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors with Significant Losses to Contact the Firm Before November 2, 2026 (Newsfile)
Sep-07-26 07:30AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights UNCY (Business Wire)
Sep-01-26 07:05AM	Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-12-26 08:00AM	Unicycive Therapeutics shares rise after second-quarter loss beats forecasts (InvestorsHub) +7.80%
07:19AM	Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jun-30-26 05:34PM	UNCY Stock Clocks Worst Day In A Year Analysts Keep Buy Ratings Despite 5-12 Month Delay In Drug Approval (Stocktwits) -39.09% +12.58%
10:10AM	UNCY Stock Crashed 45% Today Why Did FDA Reject Its Kidney Disease NDA For A Second Time? (Stocktwits)
08:42AM	Loading…
08:42AM	Unicycive shares plunge after FDA issues Complete Response Letter for kidney disease drug (UNCY) (InvestorsHub)
07:05AM	Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA) (GlobeNewswire)
May-12-26 07:05AM	Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-09-26 07:05AM	Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 07:05AM	Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-17-26 09:15AM	Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile)
Feb-04-26 07:05AM	Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit (GlobeNewswire) -5.92%
Jan-29-26 09:15AM	UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission (GlobeNewswire)
07:05AM	Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission (GlobeNewswire)
Dec-29-25 07:05AM	Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Dec-01-25 01:41PM	Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf (Newsfile) -7.26%
Nov-25-25 07:05AM	Unicycive Therapeutics to Participate in Upcoming Investor Events in December (GlobeNewswire)
Nov-12-25 07:05AM	Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +7.31%
Nov-03-25 07:05AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire) -6.53%
Oct-30-25 07:05AM	Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference (GlobeNewswire)
07:05AM	Loading…
Oct-28-25 07:05AM	Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End (GlobeNewswire) -9.92%
Oct-14-25 09:50AM	Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before October 14, 2025 (Newsfile)
Oct-13-25 05:31PM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY (PR Newswire)
Oct-08-25 05:13PM	Investors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before October 14, 2025 (Newsfile)
Oct-02-25 08:04AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY (PR Newswire)
Sep-26-25 09:00AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY (PR Newswire) +7.49%
Sep-25-25 03:19PM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights UNCY (Business Wire)
Aug-26-25 07:00AM	Unicycive Therapeutics to Participate in Upcoming Investor Events in September (GlobeNewswire)
Aug-22-25 08:45AM	Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 14, 2025 to Discuss Your Rights - UNCY (PR Newswire)
Aug-21-25 07:05AM	Shareholders who lost money in shares of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Should Contact Wolf Haldenstein Immediately. (PR Newswire)
Aug-18-25 07:05AM	Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease (GlobeNewswire) -13.19%
Aug-14-25 07:00AM	Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-24-25 08:00AM	Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology (GlobeNewswire) +5.21%
Jul-08-25 08:30AM	Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +5.97%
Jul-07-25 07:00AM	Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference (GlobeNewswire)
Jun-30-25 07:05AM	Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -29.85%
Jun-17-25 07:00AM	Unicycive Therapeutics, Inc. Announces Reverse Stock Split (GlobeNewswire) -8.96%
Jun-10-25 06:00AM	Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -40.88%
May-22-25 07:00AM	Unicycive Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-21-25 07:00AM	Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders (GlobeNewswire) -5.00%
May-14-25 07:15AM	Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -7.83%
Apr-10-25 08:00AM	Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis (GlobeNewswire)
Apr-01-25 07:00AM	Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.03%
Mar-31-25 07:00AM	Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.37%
Mar-26-25 11:59AM	DaVita Stock Declines 1.2% in 3 Months: Here's How to Play (Zacks)
Mar-13-25 07:00AM	Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia (GlobeNewswire)
Feb-20-25 07:00AM	Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 (GlobeNewswire)
Jan-28-25 07:00AM	Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science (GlobeNewswire) -5.44%
Jan-07-25 07:00AM	Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science (GlobeNewswire)
Dec-17-24 07:00AM	Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics (GlobeNewswire)
Nov-21-24 07:00AM	Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 07:15AM	Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-11-24 07:00AM	Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -9.63%
Oct-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire) +20.24%
Oct-16-24 04:35PM	Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 (GlobeNewswire) +11.39%
11:43AM	Results of Phase I trial shed positive light on UNI-494 for acute kidney injury (Clinical Trials Arena)
Oct-14-24 07:03AM	Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Oct-11-24 07:03PM	Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc (GuruFocus.com)
Oct-09-24 07:03AM	Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers (GlobeNewswire)
Sep-24-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +6.98%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
07:03AM	Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 (GlobeNewswire)
Sep-05-24 07:03AM	Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-03-24 07:03AM	Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis (GlobeNewswire) -5.89%
Aug-26-24 07:03AM	Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 (GlobeNewswire)
Aug-14-24 07:10AM	Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) +34.03%
Jul-17-24 07:03AM	Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO) (GlobeNewswire) -6.99%
Jul-11-24 07:03AM	Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference (GlobeNewswire)
Jul-10-24 07:03AM	Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Jul-01-24 07:03AM	Unicycive Therapeutics Joins Russell Microcap Index (GlobeNewswire) +7.76%
Jun-25-24 07:30AM	Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial (GlobeNewswire) -26.76%
May-28-24 07:03AM	Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress (GlobeNewswire) -11.65%
May-23-24 07:03AM	Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference (GlobeNewswire)
May-15-24 07:03AM	Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting (GlobeNewswire)
May-13-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:16PM	Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 07:00AM	3 Top Penny Stocks to Buy for Explosive Returns: April Edition (InvestorPlace)
Apr-29-24 01:37PM	These 2 Strong Buy Penny Stocks Could Rally to $9, Says Piper Sandler (TipRanks) +18.45%
Apr-10-24 07:03AM	Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Mar-28-24 10:53PM	UNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -5.48%
04:15PM	Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 07:03AM	Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress (GlobeNewswire)
Mar-14-24 07:03AM	Unicycive Announces $50 Million Private Placement (GlobeNewswire)
Mar-13-24 07:03AM	Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference (GlobeNewswire)
Mar-07-24 04:12PM	Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) (GlobeNewswire)
Mar-04-24 07:03AM	Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients (GlobeNewswire) -6.88%
Feb-14-24 07:03AM	Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting (GlobeNewswire) +10.48%
Jan-29-24 07:03AM	Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference (GlobeNewswire) +7.43%
Jan-24-24 09:39AM	Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Vivo Opportunity Fund Holdings	Director	Jun 30 '26	Proposed Sale	5.28	1,789,916	9,450,756		Jul 01 05:48 PM

Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive's second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

MPADr. Shalabh K. Gupta M.D.

Executive Vice President of Pharmaceutical and Business OperationsDr. Pramod Gupta Ph.D.

Executive Vice President of Corporate StrategyMr. Douglas Jermasek M.B.A.

Chief Financial OfficerMr. John W. Townsend CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

UNCY

Unicycive Therapeutics Inc

Upgrade your Finviz experience